A Phase, I Prospective, Randomized, Double-Blinded, Placebo-controlled, Trial to Evaluate the Safety and Potential Efficacy of Longeveron Allogeneic Human Mesenchymal Stem Cell (LMSCs) Infusion Versus Placebo in Patients With Alzheimer's Disease.

Trial Profile

A Phase, I Prospective, Randomized, Double-Blinded, Placebo-controlled, Trial to Evaluate the Safety and Potential Efficacy of Longeveron Allogeneic Human Mesenchymal Stem Cell (LMSCs) Infusion Versus Placebo in Patients With Alzheimer's Disease.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Aug 2018

At a glance

  • Drugs Mesenchymal stem cell therapy-Longeveron (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Sponsors Longeveron
  • Most Recent Events

    • 23 May 2018 This trial is also being conducted at the Miami Jewish Health Systems, according to a Longeveron media release.
    • 10 Jun 2017 Biomarkers information updated
    • 10 May 2017 According to a Longeveron media release, based on the recommendation of an independent Data Monitoring Committee (DMC) which reviewed data (n=5) from the safety run-in phase, the company will start enrolling patients in the second cohort.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top